Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | KRAS | P01116 | 1/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18383120 | 0.85 | MAPT (0.69) | HTTMAPTCYP3A4ALDH1A1TSHR | |
| SCHEMBL8552151 | 0.84 | ALDH1A1 (0.71) | HTTMAPTCYP3A4ALDH1A1TSHR | |
| SCHEMBL8998008 | 0.82 | KDM4E (0.72) | HTTMAPTCYP3A4ALDH1A1TSHR | |
| SCHEMBL3078541 | 0.82 | HTT (0.57) | HTTMAPTCYP3A4ALDH1A1TSHR | |
| SCHEMBL26473490 | 0.82 | MAPT (0.65) | HTTMAPTCYP3A4ALDH1A1TSHR | |
| SCHEMBL4423600 | 0.82 | MAPT (0.65) | HTTMAPTCYP3A4ALDH1A1TSHR | |
| SCHEMBL12641259 | 0.82 | MAPT (0.65) | HTTMAPTCYP3A4ALDH1A1TSHR | |
| SCHEMBL3196770 | 0.82 | ALDH1A1 (0.73) | HTTMAPTCYP3A4ALDH1A1TSHR | |
| SCHEMBL9664534 | 0.82 | MAPT (0.65) | HTTMAPTCYP3A4ALDH1A1TSHR | |
| SCHEMBL4921978 | 0.81 | KDM4E (0.70) | HTTMAPTCYP3A4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0101408-B1 | MONOAZO DYESTUFFS, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1986-05-07 | — | — | EP | claimed |
| WO-2023065716-A1 | POLYPEPTIDE AND APPLICATION THEREOF AS CCK RECEPTOR AGONIST/ANTAGONIST | 中国科学院香港创新研究院再生医学与健康创新中心有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-20220162186-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | EMORY UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| WO-2020191208-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-3653054-A1 | COMPOSITION FOR INHIBITION OF INSECT SENSING | Vanderbilt University (US) | 2020-05-20 | — | — | EP | disclosed |
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| WO-2007014258-A2 | GROWTH HORMONE SECRETAGOGUES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2007-02-01 | — | — | WO | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-6872835-B2 | Process for preparation of fused pyrroles | JAPAN SCIENCE & TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | disclosed |
| EP-1302459-B1 | PROCESSES FOR PREPARATION OF FUSED PYRROLES | JAPAN SCIENCE & TECH AGENCY (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20040049054-A1 | Process for preparation of fused pyrroles | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1302459-A1 | PROCESSES FOR PREPARATION OF FUSED PYRROLES | Japan Science and Technology Corporation (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-4069337-A | 2-SUBSTITUTED-INDOLE-1-LOWER-ALKANECARBOXAMIDES HAVING ANTI-SECRETORY OR ANTI-ULCER ACTIVITY | STERLING DRUG INC. (US) | 1978-01-17 | — | — | US | disclosed |
| US-4021448-A | ANTISECRETORY AND ANTIULCER ACTIVITIES | STERLING DRUG INC. (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | HTT 4475/4885MAPT 2817/4885CYP3A4 1363/4885 |
| US-20040049054-A1 | Process for preparation of fused pyrroles | IDO1, IDO2, PAH | HTT 708/4885MAPT 3087/4885CYP3A4 230/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | HTT 4764/4885MAPT 3825/4885CYP3A4 1503/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | HTT 4475/4885MAPT 2817/4885CYP3A4 1363/4885 |
| US-20220162186-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | PTGER2, PTGES2, PTGES | HTT 4594/4885MAPT 3503/4885CYP3A4 1548/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | HTT 1081/4885MAPT 1275/4885CYP3A4 1813/4885 |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | CDK12, CDK1, CDK13 | HTT 3052/4885MAPT 449/4885CYP3A4 1079/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | HTT 1033/4885MAPT 4377/4885CYP3A4 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.